Anzeige
Mehr »
Mittwoch, 05.11.2025 - Börsentäglich über 12.000 News
SuperBuzz explodiert um 20% nach Mega-Deal mit NASDAQ-Werberiesen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2R7AB | ISIN: XS2049769297 | Ticker-Symbol:
Frankfurt
04.11.25 | 17:21
92,77 
0,00 % 0,00
Branche
Gesundheitswesen
Aktienmarkt
Anleihen
1-Jahres-Chart
MOLNLYCKE HOLDING AB Chart 1 Jahr
5-Tage-Chart
MOLNLYCKE HOLDING AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,00004.11.
PR Newswire
266 Leser
Artikel bewerten:
(1)

Mölnlycke Health Care: Mölnlycke establishes first wound care manufacturing site in China

CHANGSHU, China and GOTHENBURG, Sweden, Nov. 5, 2025 /PRNewswire/ -- Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke's growth journey and the beginning of localised manufacturing in one of the world's fastest-growing MedTech markets.

Mölnlycke establishes first wound care manufacturing site in China, marked by a commencement ceremony in Changshu. (PRNewsfoto/Mölnlycke Health Care)

"Our site in Changshu marks another step forward in Mölnlycke's ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China," says Zlatko Rihter, CEO of Mölnlycke.

The manufacturing site, spanning 10,000 m2, will be set up in accordance with Mölnlycke's global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. This strategic move will help future-proof Mölnlycke's growth in China, laying the foundation for future capacity expansion and local job creation.

"This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions," adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.

The Changshu site strengthens Mölnlycke's position in Asia and aligns with China's growing demand for advanced, locally manufactured healthcare solutions.

For more information, please contact:

Jamie Smith
Media Relations Manager
Email: jamie.smith@molnlycke.com
Phone: +46 (0)722-553573

About Mölnlycke

Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com

Photo - https://mma.prnewswire.com/media/2813358/Molnlycke_Health_Care.jpg
Logo - https://mma.prnewswire.com/media/2812160/Molnlycke_Logo.jpg

Mölnlycke Logo (PRNewsfoto/Mölnlycke Health Care)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/molnlycke-establishes-first-wound-care-manufacturing-site-in-china-302604483.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.